FDA Approves Genentech’s Tecentriq Hybreza, First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy $RHHBY

Sep 12, 2024, 09:30 PM

The FDA has approved Genentech's Tecentriq Hybreza, making it the first subcutaneous anti-PD-(L)1 cancer immunotherapy available in the U.S. This approval marks a significant step in cancer treatment, providing a more accessible option for patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma. Halozyme's ENHANZE technology played a crucial role in the development of this subcutaneous formulation. The stocks for Genentech ($RHHBY) and Halozyme ($HALO) are likely to be impacted by this approval.